Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
Prevention is Primary

HIV Postexposure Prophylaxis in the 21st Century

David K. HendersonComments to Author 
Author affiliation: Warren G. Magnuson Clinical Center, Bethesda, Maryland, USA

Main Article

Table

Clinical trials assessing the efficacy of antiretroviral agents in preventing maternal-fetal transmission of HIV

Study (ref) Regimena Timingb Outcome
Connor (15) ZDV A+L+P 8.3% vs 25.5%
Shaffer (28) ZDV A+L 9.4% vs 18.9%
Wiktor (29) ZDV A+L 12.2% vs 21.7%
Dabis (30) ZDV A+L+P 18.0% vs 27.5%
Wade (31) ZDV A+L+P 6.1% vs 26.6%
ZDV L+P 10.0% vs 26.6%
ZDV P (<48 hr) 9.3% vs 26.6%
ZDV P (>72 hr) 18.4% vs 26.6%
Bulterys (22) ZDV A+L+P 8.2% vs 15.5%
ZDV L+P 8.6% vs 15.5%
ZDV P 8.1% vs 15.5%
Saba (23) ZDV+3TC A+L+P 52% reduction
ZDV+3TC L+P 40% reduction
ZDV+3TC L no reduction
Blanche (24) ZDV+3TC A+L+P 2.6%
ZDV A+L+P 6.5%
Guay (25) ZDV L+P 25.1%
NVP L+P 13.1%

aZDV = zidovudine (azidothymidine); 3TC = lamivudine; NVP = nevirapine
bA - Prenatal therapy (usually beginning at 36 weeks); L - Therapy during labor and delivery; P - Postpartum treatment of infant.

Main Article

References
  1. Henderson  DK, Gerberding  JL. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis. J Infect Dis. 1989;160:321–7. DOIPubMedGoogle Scholar
  2. Henderson  DK. Post-exposure chemoprophylaxis for occupational exposure to HIV-1: current status and prospects for the future. Am J Med. 1991;91(Suppl 3B):S312–9. DOIGoogle Scholar
  3. Spira  AI, Marx  PA, Patterson  BK, Mahoney  J, Koup  RA, Wolinsky  SM, Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med. 1996;183:215–25. DOIPubMedGoogle Scholar
  4. Pope  M, Gezelter  S, Gallo  N, Hoffman  L, Steinman  RM. Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells. J Exp Med. 1995;182:2045–56. DOIPubMedGoogle Scholar
  5. Ruprecht  RM, Bronson  R. Chemoprevention of retroviral infection: success is determined by virus inoculum strength and cellular immunity. DNA Cell Biol. 1994;13:59–66. DOIPubMedGoogle Scholar
  6. Clerici  M, Levin  JM, Kessler  HA, Harris  A, Berzofsky  JA, Landay  AL, HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA. 1994;271:42–6. DOIPubMedGoogle Scholar
  7. Pinto  LA, Sullivan  J, Berzofsky  JA, Clerici  M, Kessler  HA, Landay  AL, ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest. 1995;96:867–76. DOIPubMedGoogle Scholar
  8. D'Amico  R, Pinto  LA, Meyer  P, Landay  AL, Harris  AA, Clerici  M, Effect of zidovudine postexposure prophylaxis on the development of HIV- specific cytotoxic T-lymphocyte responses in HIV-exposed health care workers. Infect Control Hosp Epidemiol. 1999;20:428–30. DOIPubMedGoogle Scholar
  9. Henderson  DK, Saah  AJ, Zak  BJ, Kaslow  RA, Lance  HC, Folks  T, Risk of nosocomial infection with human T-cell lymphotropic virus type III/lymphadenopathy-associated virus in a large cohort of intensively exposed health care workers. Ann Intern Med. 1986;104:644–7.PubMedGoogle Scholar
  10. Böttiger  D, Johansson  NG, Samuelsson  B, Zhang  H, Putkonen  P, Vrang  L, Prevention of simian immunodeficiency virus, SIV, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS. 1997;11:157–62. DOIPubMedGoogle Scholar
  11. Tsai  CC, Follis  KE, Sabo  A, Beck  TW, Grant  RF, Bischofberger  N, Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995;270:1197–9. DOIPubMedGoogle Scholar
  12. Tsai  CC, Emau  P, Follis  KE, Beck  TW, Benveniste  RE, Bischofberger  N, Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998;72:4265–73.PubMedGoogle Scholar
  13. Otten  R, Smith  D, Pullium  J, Adams  D, Jackson  E, Jaffe  H, Potent efficacy of post-exposure prophylaxis (PEP) up to 72 hours after intra-vaginal exposure of pig-tailed macaques with a human-derived retrovirus (HIV-2). Proceedings of the 4th Decennial Conference on Nosocomial Infections; 2000 Mar 5-9; Atlanta, Georgia. Centers for Disease Control and Prevention; 2000.
  14. Lindegren  ML, Byers  RH Jr, Thomas  P, Davis  SF, Caldwell  B, Rogers  M, Trends in perinatal transmission of HIV/AIDS in the United States. JAMA. 1999;282:531–8. DOIPubMedGoogle Scholar
  15. Connor  EM, Sperling  RS, Gelber  R, Kiselev  P, Scott  G, O'Sullivan  MJ, Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173–80. DOIPubMedGoogle Scholar
  16. Sperling  RS, Shapiro  DE, Coombs  RW, Todd  JA, Herman  SA, McSherry  GD, Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1996;335:1621–9. DOIPubMedGoogle Scholar
  17. Eastman  PS, Shapiro  DE, Coombs  RW, Frenkel  LM, McSherry  GD, Britto  P, Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis. 1998;177:557–64. DOIPubMedGoogle Scholar
  18. Frenkel  LM, Cowles  MK, Shapiro  DE, Melvin  AJ, Watts  DH, McLellan  C, Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis. 1997;175:971–4. DOIPubMedGoogle Scholar
  19. Kind  C, Rudin  C, Siegrist  CA, Wyler  CA, Biedermann  K, Lauper  U, Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. AIDS. 1998;12:205–10. DOIPubMedGoogle Scholar
  20. Kind  C. Mother-to-child transmission of human immunodeficiency virus type 1: influence of parity and mode of delivery. Paediatric AIDS Group of Switzerland. Eur J Pediatr. 1995;154:542–5. DOIPubMedGoogle Scholar
  21. Simpson  BJ, Shapiro  ED, Andiman  WA. Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:145–52. DOIPubMedGoogle Scholar
  22. Bulterys  M, Orloff  S, Abrams  E. Impact of zidovudine post-perinatal exposure prophylaxis (PPEP) on vertical HIV-1 transmission: a prospective cohort in four U.S. Cities [Abstract 15]. Global Strategies for the Prevention of HIV Transmisison from Mothers to Infants. Toronto, Ontario, Canada; Sept 1-6 1999.
  23. Saba  J. the PETRA Trial Study Team. Interim analysis of early efficacy of three short ZDV/3TC combinations regimens to prevent mother-to-child transmission of HIV-1: the PETRA trial [Abstract S7]. Proceedings from the 6th Annual Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois; 31 Jan-4 Feb 1999.
  24. Blanche  S. Zidovudine-Lamivudine for Prevention of Mother to Child HIV-1 Transmission [Abstract 267]. Proceedings from the 6th Annual Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois; 31 Jan-4 Feb 1999.
  25. Guay  LA, Musoke  P, Fleming  T, Bagenda  D, Allen  M, Nakabiito  C, Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795–802.PubMedGoogle Scholar
  26. Marseille  E, Kahn  JG, Mmiro  F, Guay  L, Musoke  P, Fowler  MG, Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet. 1999;354:803–9.PubMedGoogle Scholar
  27. Lorenzi  P, Spicher  VM, Laubereau  B, Hirschel  B, Kind  C, Rudin  C, Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS. 1998;12:F241–7. DOIPubMedGoogle Scholar
  28. Shaffer  N, Chuachoowong  R, Mock  PA, Bhadrakom  C, Siriwasin  W, Young  NL, Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group [see comments]. Lancet. 1999;353:773–80. DOIPubMedGoogle Scholar
  29. Wiktor  SZ, Ekpini  E, Karon  JM, Nkengasong  J, Maurice  C, Severin  ST, Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet. 1999;353:781–5. DOIPubMedGoogle Scholar
  30. Dabis  F, Msellati  P, Meda  N, Welffens-Ekra  C, You  B, Manigart  O, Six-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo- controlled multicentre trial. DITRAME Study Group. Diminution de la transmission mere-enfant. Lancet. 1999;353:786–92. DOIPubMedGoogle Scholar
  31. Wade  NA, Birkhead  GS, Warren  BL, Charbonneau  TT, French  PT, Wang  L, Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409–14. DOIPubMedGoogle Scholar
  32. Cardo  DM, Culver  DH, Ciesielski  CA, Srivastava  PU, Marcus  R, Abiteboul  D, A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997;337:1485–90. DOIPubMedGoogle Scholar
  33. Henderson  DK. Postexposure treatment of HIV--taking some risks for safety's sake. N Engl J Med. 1997;337:1542–3. DOIPubMedGoogle Scholar
  34. Bangsberg  D, Goldschmidt  RH. Postexposure prophylaxis for occupational exposure to HIV. JAMA. 1999;282:1623–4. DOIPubMedGoogle Scholar
  35. Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep. 1998;47(RR-7):1–33.PubMedGoogle Scholar
  36. Beltrami  EM, Luo  C-C, De la Torre  M. HIV Transmission after an occupational exposure despite postexposure prophylaxis with a combination drug regimen. Proceedings of the 4th Decennial Conference on Nosocomial Infections. Atlanta, Georgia; Mar 5-9 2000; Centers for Disease Control and Prevention.
  37. Descamps  D, Flandre  P, Calvez  V, Peytavin  G, Meiffredy  V, Collin  G, Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team). JAMA. 2000;283:205–11. DOIPubMedGoogle Scholar
  38. Bangsberg  D, Hecht  F, Charlebois  E, Zolopa  AR, Holodniy  M, Sheiner  L, Adherence to protease inhibitors, HIV-1 load, and development of drug resistance In an indigent population. AIDS. 2000;14:357–66. DOIPubMedGoogle Scholar
  39. Devereux  HL, Youle  M, Johnson  MA, Loveday  C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS. 1999;13:F123–7. DOIPubMedGoogle Scholar
  40. Blanche  S, Tardieu  M, Rustin  P, Slama  A, Barret  B, Firtion  G, Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084–9. DOIPubMedGoogle Scholar
  41. Schmitt  J, Taylor  J, Fahey  B, White  T, Henderson  D. Sustained decrease in percutaneous injuries (PI) in temporal association with universal/standard precautions (UP/SP) and PI-reducing strategies (PIRS). Proceedings of the 4th Decennial Conference on Nosocomial Infections. Atlanta, Georgia; Mar 5-9, 2000; Centers for Disease Control and Prevention.
  42. Haiduven  DJ, Phillips  ES, Clemons  KV, Stevens  DA. Percutaneous injury analysis: consistent categorization, effective reduction methods, and future strategies. Infect Control Hosp Epidemiol. 1995;16:582–9. DOIPubMedGoogle Scholar
  43. Haiduven  DJ, Stevens  DA. Eight-year analysis of percutaneous injuries: categorization, effective reduction methods and future strategies [Abstract J141]. Proceedings from the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, Florida; Oct 4-7, 1994; American Society for Microbiology.
  44. Beekmann  SE, Vlahov  D, Koziol  DE, McShalley  ED, Schmitt  JM, Henderson  DK. Temporal association between implementation of universal precautions and a sustained, progressive decrease in percutaneous exposures to blood. Clin Infect Dis. 1994;18:562–9. DOIPubMedGoogle Scholar

Main Article

Page created: April 17, 2012
Page updated: April 17, 2012
Page reviewed: April 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external